Reference health
Pharmacogenetics of multiple sclerosis
74/74 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
5 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 74 checked references that resolve
resolves10.1007/s11096-010-9446-1
From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics
resolves10.2174/138920011795495268
The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
resolves10.1097/FPC.0b013e3281299169
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
resolves10.1016/j.jneuroim.2014.11.017
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis
resolves10.1007/s40263-013-0117-3
Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis
resolves10.1016/j.bbadis.2010.07.007
Inflammation, demyelination, and degeneration — Recent insights from MS pathology
resolves10.2165/11591110-000000000-00000
The Mechanism of Action of Interferon-β in Relapsing Multiple Sclerosis
resolves10.3109/08923979809034808
Effect of Propranolol and IFN-β on the Induction of MHC Class II Expression and Cytokine Production by IFN-γ in THP-1 Human Monocytic Cells
resolves10.1089/jir.2007.0018
Diminished Myelin-Specific T Cell Activation Associated with Increase in CTLA4 and Fas Molecules in Multiple Sclerosis Patients Treated with IFN-
<i>β</i>
resolves10.1016/0165-5728(95)00072-A
Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells
resolves10.1016/j.jneuroim.2009.10.013
Effect of IFN-ß therapy on the frequency and function of CD4+CD25+ regulatory T cells and Foxp3 gene expression in relapsing–remitting multiple sclerosis (RRMS): A preliminary study
resolves10.1001/archneur.65.11.1434
Interferon Beta–Induced Restoration of Regulatory T-Cell Function in Multiple Sclerosis Is Prompted by an Increase in Newly Generated Naive Regulatory T Cells
resolves10.1016/j.clim.2009.09.008
IFNβ-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: A longitudinal 1-year study
resolves10.1007/s00415-002-0699-z
Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid
resolves10.4049/jimmunol.170.9.4483
Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells
resolves10.1111/j.1468-1331.2005.01084.x
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
resolves10.1016/j.jneuroim.2009.06.011
Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis
resolves10.1073/pnas.0502187102
Induction of CD4
<sup>+</sup>
CD25
<sup>+</sup>
regulatory T cells by copolymer-I through activation of transcription factor Foxp3
resolves10.4049/jimmunol.176.11.7119
Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis
resolves10.1172/JCI200214380
Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis
resolves10.1212/WNL.45.7.1268
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
resolves10.1212/WNL.57.11.1976
HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis
resolves10.1002/ana.64
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
resolves10.1212/01.wnl.0000237994.95410.ce
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
resolves10.1136/jmedgenet-2014-102348
HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-β therapy in multiple sclerosis
resolves10.1371/journal.pone.0090479
Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis
resolves10.1038/sj.gene.6363946
Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis
resolves10.1016/j.clpt.2005.08.018
Pharmacogenomics of responsiveness to interferon IFN-β treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes
resolves10.1038/gene.2011.18
Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis
resolves10.1111/ene.12193
Roles of the ubiquitin peptidase <i><scp>USP</scp>18</i> in multiple sclerosis and the response to interferon‐<i>β</i> treatment
resolves10.1016/j.jneuroim.2005.12.002
An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients
resolves10.1111/j.1468-1331.2004.01102.x
IL‐10 promoter haplotype influence on interferon treatment response in multiple sclerosis
resolves10.2217/pgs.12.161
Allelic Combinations of Immune-Response Genes as Possible Composite Markers of IFN-β Efficacy in Multiple Sclerosis Patients
resolves10.1371/journal.pone.0062540
Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
resolves10.1177/1352458510393263
CD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatment
resolves10.1016/S0165-5728(02)00215-1
The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β
resolves10.1111/j.1600-0404.2005.00415.x
HLA class II and response to interferon-beta in multiple sclerosis
resolves10.1016/j.jneuroim.2009.01.012
HLA class I and II alleles and response to treatment with interferon-beta in relapsing–remitting multiple sclerosis
resolves10.2217/pgs.09.41
Genetic Polymorphisms, their Allele Combinations and IFN-β Treatment Response in Irish Multiple Sclerosis Patients
resolves10.1016/j.jneuroim.2005.02.010
IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
resolves10.1016/j.jneuroim.2011.08.004
IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis
resolves10.1016/j.nrl.2010.06.003
Influencia del polimorfismo del gen de la APOE en la respuesta al tratamiento con interferón beta en esclerosis múltiple
resolves10.1146/annurev.immunol.26.021607.090400
The IRF Family Transcription Factors in Immunity and Oncogenesis
resolves10.1007/s00109-009-0484-x
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation
resolves10.1172/JCI29251
Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis
resolves10.1093/jnen/61.7.597
Subtractive Expression Cloning Reveals High Expression of CD46 at the Blood-Brain Barrier
resolves10.1001/archneurol.2008.47
Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple Sclerosis
resolves10.1016/j.jneuroim.2006.10.011
Pharmacogenetics of MXA SNPs in interferon-β treated multiple sclerosis patients
resolves10.1001/archneurol.2009.150
Genome-wide Scan of 500 000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis
resolves10.1111/ahg.12095
Addressing Population‐Specific Multiple Testing Burdens in Genetic Association Studies
resolves10.2217/14622416.9.5.639
Pharmacogenomics of the Response to IFN-β in Multiple Sclerosis: Ramifications from the First Genome-Wide Screen
resolves10.1534/genetics.105.048090
A Markov Chain Monte Carlo Technique for Identification of Combinations of Allelic Variants Underlying Complex Diseases in Humans
resolves10.2217/pgs.11.136
Allelic Combinations of Immune-Response Genes Associated with Glatiramer Acetate Treatment Response in Russian Multiple Sclerosis Patients
resolves10.1016/j.msard.2013.02.005
HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis
resolves10.1134/S0026893311060185
Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy
resolves10.1016/S1474-4422(08)70200-X
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
resolves10.2217/pgs.14.26
Comparative Pharmacogenetics of Multiple Sclerosis: IFN-β Versus Glatiramer Acetate
resolves10.2217/pgs.09.33
United Europeans for Development of Pharmacogenomics In Multiple Sclerosis Network
The 5 references without a DOI — listed, not checked
no DOI — not checkedInterferon in relapsing-remitting multiple sclerosis.
no DOI — not checkedGlatiramer acetate for multiple sclerosis.
no DOI — not checkedThe receptor of the type I interferon family.
no DOI — not checkedAssociation of CD58 polymorphism with multiple sclerosis and response to interferon therapy in a subset of Iranian population.
no DOI — not checkedBoĭko AN. Multiple sclerosis as a polygenic disease: an update.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1097/fpc.0000000000000194"><img src="https://citestamp.com/citestamped/10.1097/fpc.0000000000000194/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1097/fpc.0000000000000194)